There is strong evidence that circulating markers of systemic inflammation can predict long-term cognitive decline among older people with type 2 diabetes.

Data analysis suggests that weight changes during weight loss attempts may raise the risk of cardiovascular disease and mortality in people with type 2 diabetes. 

In the SWEET project experience, a large cohort of patients was started on either an insulin pump, glucose sensor, or both to compare the HbA1c levels and weight gain while on their new therapy.

Verapamil might serve as a potential breakthrough allowing type one diabetes patients to produce their insulin. 

The analysis of lipid profiling in the prediction of risk of developing type 2 diabetes and cardiovascular diseases can aid in recommending lifestyle changes and diet before the development of the diseases.

Studies have shown that emotional eating and other eating behaviors could reduce weight loss when taking GLP-1 receptor agonists.

Studies have found that average levels of moderate caffeine intake are related to lower cardiovascular risk.

New retrospective study results compare the two most primarily prescribed antidiabetic medication classes in addition to metformin to determine the impact on the incidence of CV events in patients with T2DM.

According to the research presented by Dr. Petter Bjornstad from the University of Colorado Anschutz Medical Campus, the risk of microvascular complications increases by the time of young adulthood in patients who have diabetes in youth.

Studies have found that there may be a benefit in implementing a calorie-restricted diet in patients with type 2 diabetes to improve glomerular hyperfiltration.